A large multicenter study from 2016 reported that HER-2 overexpression was found in 35.8% of UTUC patients undergoing RNU, who had an increased risk of an advanced tumor stage, high tumor grade and LVI. This evidence concerns the gene ERBB2 and neoplasm.